These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Two advances ease burden of CMV treatment.
    Author: Vazquez E.
    Journal: Posit Aware; 1996; 7(3):8. PubMed ID: 11363430.
    Abstract:
    Vitrasert implants for cytomegalovirus (CMV) retinitis won Food and Drug Administration (FDA) approval in March 1996. The implant delivers Hoffmann-La Roche's ganciclovir (Cytovene) directly into the eye for up to 8 months and slows disease progression. Twelve percent of patients suffered retinal detachments, although this may have been caused by the disease and not the treatment. An FDA advisory panel also recommended the use of intravenous cidofovir for treatment of CMV retinitis.
    [Abstract] [Full Text] [Related] [New Search]